MRI measures of hypothalamic injury are associated with glucagon‐like peptide‐1 receptor agonist treatment response in people with hypothalamic obesity
- 2 March 2021
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (7) , 1532-1541
Abstract
Aim: To evaluate whether neuroimaging‐delineated regions of hypothalamic injury are associated with a differential treatment response to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) in patients with hypothalamic obesity (HO). Materials and Methods: We performed a prespecified secondary analysis of a randomized, multicentre, double‐blind, placebo‐controlled trial of people aged 10–25 years with hypothalamic injury and HO randomized to the GLP‐1RA exenatide once‐weekly (ExQW) or placebo for 36 weeks. Subjects underwent MRI prior to enrolment and the degree of hypothalamic damage was assessed using an integrative hypothalamic lesion score (HLS). Mammillary body (MB) damage was specifically determined. The main clinical endpoints were % change in body mass index (BMI) and change in % body fat. Nested ANCOVA models including a treatment × imaging measure interaction were compared using partial F‐tests to assess whether the effect of ExQW treatment differed by severity of hypothalamic damage. Results: Complete data were available in 35/42 randomized participants (placebo, n = 15; ExQW, n = 20). ExQW‐treated patients with worse HLS or bilateral MB damage had greater reductions in % body fat at 36 weeks (interaction coefficient estimates for HLS: −0.9%, 95% CI –1.6% to −0.2%, p = .02; for MB damage: −7.4%, 95% CI –10.1% to −4.7%, p < .001, respectively) but not for BMI % change. Similarly, patients with more damaged and smaller MB cross‐sectional areas had greater reductions in % body fat following ExQW (interaction coefficient estimate 0.3%, 95% CI 0.2%–0.4%, p < .001). Conclusions: In people with HO, greater hypothalamic damage as determined by MRI, in particular MB injury, is associated with greater reductions in adiposity following GLP‐1RA treatment.Keywords
Funding Information
- National Center for Advancing Translational Sciences
This publication has 39 references indexed in Scilit:
- Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-upEuropean Journal of Endocrinology, 2011
- Hypothalamic Obesity in Patients with Craniopharyngioma: Profound Changes of Several Weight Regulatory CircuitsFrontiers in Endocrinology, 2011
- Hypothalamic Obesity following Craniopharyngioma Surgery: Results of a Pilot Trial of Combined Diazoxide and Metformin TherapyInternational Journal of Pediatric Endocrinology, 2011
- Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvementJournal of neurosurgery. Pediatrics, 2007
- Projections from the hippocampal region to the mammillary bodies in macaque monkeysEuropean Journal of Neuroscience, 2005
- Gut feeling – the secret of satiety?Clinical Medicine, 2005
- Glucagon-like peptide 1 (GLP-1) and eatingPhysiology & Behavior, 2004
- Perioperative Dexamethasone Treatment in Childhood CraniopharyngiomaExperimental and Clinical Endocrinology & Diabetes, 2003
- MEMORY AND THE REGION OF THE MAMMILLARY BODIESProgress in Neurobiology, 1998
- Obesity following combination of rostrolaterial to VMH cut and contralateral mammillary area lesion.Journal of Comparative and Physiological Psychology, 1972